Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Executive Summary

Lilly agreed to pay $1.4 billion in criminal and civil fines and pled guilty to misbranding its antipsychotic drug Zyprexa in a settlement with the U.S. Department of Justice. Despite the record-breaking sum, however, the terms in the accompanying corporate integrity agreement are similar to previous CIAs
Advertisement

Related Content

Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled
Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More
Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior
Zyprexa Settlement With W. Virginia Shows States Can Benefit In Solo Suits
Lesson from Lilly’s Zyprexa Settlement: Be Proactive In Monitoring Sales Reps
Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases
Bextra Settlement Coming Soon: Industry Should Brace For Impact
Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?
Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges

Topics

Advertisement
UsernamePublicRestriction

Register

PS050563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel